After finishing at $8.19 in the prior trading day, Travere Therapeutics Inc (NASDAQ: TVTX) closed at $8.04, down -1.83%. In other words, the price has decreased by -$0.15 from its previous closing price. On the day, 1424519 shares were traded. TVTX stock price reached its highest trading level at $8.16 during the session, while it also had its lowest trading level at $7.80.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of TVTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.41 and its Current Ratio is at 3.47. In the meantime, Its Debt-to-Equity ratio is 2.02 whereas as Long-Term Debt/Eq ratio is at 1.99.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Citigroup on December 05, 2023, Upgraded its rating to Buy and sets its target price to $10 from $7 previously.
On November 20, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $7.
Wells Fargo Downgraded its Overweight to Equal Weight on September 22, 2023, whereas the target price for the stock was revised from $24 to $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 01 when Dube Eric M sold 19,122 shares for $8.70 per share. The transaction valued at 166,435 led to the insider holds 350,600 shares of the business.
REED ELIZABETH E sold 4,764 shares of TVTX for $41,495 on Feb 01. The SVP, GC & CORPORATE SECRETARY now owns 76,270 shares after completing the transaction at $8.71 per share. On Feb 01, another insider, ROTE WILLIAM E., who serves as the SENIOR VICE PRESIDENT, R&D of the company, sold 4,764 shares for $8.71 each. As a result, the insider received 41,495 and left with 80,720 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 611.07M and an Enterprise Value of 449.00M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.08 while its Price-to-Book (P/B) ratio in mrq is 3.02. Its current Enterprise Value per Revenue stands at 3.09 whereas that against EBITDA is -1.38.
Stock Price History:
Over the past 52 weeks, TVTX has reached a high of $23.17, while it has fallen to a 52-week low of $5.25. The 50-Day Moving Average of the stock is 8.72, while the 200-Day Moving Average is calculated to be 11.23.
Shares Statistics:
The stock has traded on average 1.48M shares per day over the past 3-months and 1.29M shares per day over the last 10 days, according to various share statistics. A total of 75.37M shares are outstanding, with a floating share count of 75.01M. Insiders hold about 1.43% of the company’s shares, while institutions hold 113.66% stake in the company. Shares short for TVTX as of Feb 15, 2024 were 9.76M with a Short Ratio of 6.62, compared to 9.71M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 12.83% and a Short% of Float of 12.89%.
Earnings Estimates
Its stock is currently analyzed by 12 different market analysts. On average, analysts expect EPS of -$0.97 for the current quarter, with a high estimate of -$0.55 and a low estimate of -$1.27, while EPS last year was -$1.27. The consensus estimate for the next quarter is -$0.84, with high estimates of -$0.63 and low estimates of -$1.08.
Analysts are recommending an EPS of between -$2.28 and -$4.27 for the fiscal current year, implying an average EPS of -$3.25. EPS for the following year is -$1.73, with 12 analysts recommending between $0.16 and -$2.54.
Revenue Estimates
13 analysts predict $44.37M in revenue for the current quarter. It ranges from a high estimate of $60.85M to a low estimate of $38M. As of the current estimate, Travere Therapeutics Inc’s year-ago sales were $56.99M, an estimated decrease of -22.10% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $51.81M, a decrease of -13.20% over than the figure of -$22.10% in the same quarter last year. There is a high estimate of $66M for the next quarter, whereas the lowest estimate is $42M.
A total of 14 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $267M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $215.39M. In the same quarter a year ago, actual revenue was $145.24M, up 48.30% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $312.73M in the next fiscal year. The high estimate is $513.31M and the low estimate is $236M. The average revenue growth estimate for next year is up 45.20% from the average revenue estimate for this year.
